Acalabrutinib Study in Indian Patients With Chronic Lymphocytic Leukaemia & Relapsed and Refractory Mantle Cell Lymphoma
Condition(s):Chronic Lymphocytic Leukemia and Relapsed and Refractory Mantle Cell LymphomaLast Updated:May 15, 2023Completed
Hide Studies Not Open or Pending
Condition(s):Chronic Lymphocytic Leukemia and Relapsed and Refractory Mantle Cell LymphomaLast Updated:May 15, 2023Completed
Condition(s):Relapsed/Refractory Mantle Cell LymphomaLast Updated:December 14, 2023Active, not recruiting
Condition(s):Relapsed / Refractory Mantle Cell Lymphoma (MCL)Last Updated:September 11, 2020Unknown status
Condition(s):Recurrent Mantle Cell Lymphoma; Refractory Mantle Cell LymphomaLast Updated:January 18, 2024Recruiting
Condition(s):Mantle Cell Lymphoma; Refractory Mantle Cell Lymphoma (MCL); Relapsed Mantle Cell LymphomaLast Updated:February 6, 2024Recruiting
Condition(s):Relapsed/Refractory Mantle Cell LymphomaLast Updated:February 12, 2024Completed
Condition(s):Relapsed or Refractory Mantle Cell LymphomaLast Updated:November 7, 2018Approved for marketing
Condition(s):Lymphoma, Mantle-CellLast Updated:October 21, 2022Recruiting
Condition(s):Recurrent Mantle Cell Lymphoma; Refractory Mantle Cell LymphomaLast Updated:December 15, 2023Suspended
Condition(s):Mantle Cell Lymphoma RefractoryLast Updated:March 9, 2017Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.